SOM 3366
Alternative Names: SOM-3366Latest Information Update: 17 Sep 2024
Price :
$50 *
At a glance
- Originator SOM Biotech
- Class Neuropsychotherapeutics
- Mechanism of Action Vesicular monoamine transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Tardive dyskinesia
Most Recent Events
- 29 Apr 2024 SOM Biotech plans a phase I trial for Tardive dyskinesia in 2024 (SOM Biotech pipeline, April 2024)
- 01 Mar 2023 Preclinical trials in Tardive dyskinesia in Spain (PO) (SOM Biotech pipeline, March 2023)
- 01 Mar 2023 SOM Biotech plans a phase I trial for Tardive dyskinesia (PO) (SOM Biotech pipeline, March 2023)